Table 1.
Demographics and Baseline Characteristics
| Part 1 (Cohorts 1–6) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Trabodenoson dose groups | Part 2 (Cohort 7) | ||||||||
| Placebo (n = 24) | 200 μg (n = 6) | 400 μg (n = 6) | 800 μg (n = 6) | 1,600 μg (n = 6) | 2,400 μg (n = 6) | 3,200 μg (n = 6) | Placebo (n = 4) | Trabodenoson (n = 6) | |
| Age, years, mean (SD) | 49 (8.8) | 51 (9.0) | 45 (7.3) | 46 (9.5) | 47 (10.3) | 48 (8.9) | 52 (3.7) | 48 (10.4) | 44 (4.7) |
| Male, % | 58.3 | 66.7 | 50.0 | 50.0 | 83.3 | 83.3 | 66.7 | 75.0 | 83.3 |
| Race, % | |||||||||
| White | 87.5 | 83.3 | 50.0 | 83.3 | 66.7 | 66.7 | 33.3 | 75.0 | 33.3 |
| African American | 16.7 | 16.7 | 33.3 | 16.7 | 33.3 | 33.3 | 33.3 | 25.0 | 66.7 |
| Others | — | 16.7 | 16.7 | — | — | — | 33.3 | — | 16.7 |
| BMI, kg/m2, mean (SD) | 28.8 (3.7) | 27.2 (4.4) | 25.7 (3.0) | 23.9 (1.5) | 28.7 (2.1) | 25.5 (3.0) | 27.5 (4.5) | 29.1 (4.09) | 28.2 (4.23) |
| IOP, mmHg, mean (SD) | |||||||||
| Study eye | 11.9 (2.75) | 12.5 (2.07) | 11.8 (1.75) | 12.9 (4.67) | 12.5 (3.08) | 11.0 (2.45) | 12.1 (2.20) | — | — |
| Nonstudy eye | 10.5 (2.66) | 11.4 (1.99) | 10.9 (1.39) | 11.1 (3.79) | 11.9 (2.25) | 9.8 (2.32) | 11.3 (2.02) | — | — |
BMI, body mass index; IOP, intraocular pressure; SD, standard deviation.